comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 21:08:01 - browse：79925

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： 2 million sign

focus

WSS

Former New York Mayor de Blasio and wife announce separation, but not divorce

Condition critical? Britain's beloved but battered National Health Service turns 75

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

Ohio train derailment: Experts on toxic chemical risks

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

Medicare Advantage isn’t working — for anyone

focus

comprehensive

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Pope Francis asks Church to identify 21st

After affirmative action ruling, medical educators look to 'holistic review'

Man with guns arrested near Obama home 'attempted to evade' Secret Service: Prosecutors

Drug repurposing or repositioning? The language matters

Virtual repurposing can help discover new uses for existing drugs

Moonlake's readout produced a cash windfall. Risks remain

CDC advisory group OKs chikungunya vaccine

After affirmative action ruling, medical educators look to 'holistic review'

Childhood vaccination ad campaign launches in the U.K.

focus

Readout Newsletter: Beam, Prozac, "TechBio" and more

Readout Newsletter: Beam, Prozac, "TechBio" and more

Children’s Hospital revives plan for pedestrian bridge

STAT Madness 2024: Meet the contenders

Elisabeth Bik tackles the widespread issue of research misconduct

Elisabeth Bik tackles the widespread issue of research misconduct

entertainment

focus

knowledge

explore